Drugs / AUTX-703
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06846606 | May 2025 → Apr 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Auron Therapeutics, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Auron Therapeutics, Inc. | Results Auron Presents Preclinical Data Highlighting the Activity of AUTX-703 in Prostate Cancer at 2025 AACR Annual Meeting aurontx.com ↗
In NEPC cell lines and PDXO models treated for up to 21 days, AUTX-703 mediated potent KAT2A/KAT2B degradation, inhibited cell growth and induced cell state differentiation. |
| 2025-04-03 | Auron Therapeutics, Inc. | Results Auron Presents New Preclinical Data for AUTX-703 in Small Cell Lung Cancer (SCLC) aurontx.com ↗
In a series of experiments, Auron showed that treatment with AUTX-703 potently degraded KAT2A/B, inhibited tumor growth, and induced durable cell state differentiation across models of SCLC. |
| 2025-02-24 | Auron Therapeutics, Inc. | Regulatory Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia aurontx.com ↗
the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AUTX-703 for the treatment of patients with relapsed or refractory (r/r) acute myelogenous leukemia (AML). |
| 2025-02-04 | Auron Therapeutics, Inc. | Regulatory Auron Therapeutics Announces FDA Clearance to Initiate Clinical Development of AUTX-703 and Completion of Series B Financing aurontx.com ↗
Auron has received clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) and is initiating clinical development of AUTX-703 in hematological malignancies. |
| 2024-12-09 | Auron Therapeutics, Inc. | Results Auron Presents New Preclinical Data for AUTX-703 in AML at ASH Annual Meeting aurontx.com ↗
Overall, treatment with AUTX-703 was well-tolerated and reversed the block in cellular differentiation, resulting in a significant survival advantage in a primary patient-derived orthotopic AML model. |
| 2024-10-24 | Auron Therapeutics, Inc. | Results Auron Presents New Preclinical Data for Lead Program AUTX-703 Across Multiple Cancer Types aurontx.com ↗
In a series of experiments, Auron showed that treatment with AUTX-703 potently degraded KAT2A/B, inhibited tumor growth, and induced a more differentiated cell state across models of SCLC, NEPC and CRPC. |
| 2024-04-09 | Auron Therapeutics, Inc. | Results Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual Meeting aurontx.com ↗
In a second poster, Auron shared preclinical data from its program targeting KAT2A/B, an AURIGIN-identified histone acetyltransferase driving small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and acute myeloid leukemia (AML). |
All press releases naming this drug 10 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUTX-703 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06846606 ↗ |
| Action | Inhibit | “lysine acetyltransferase 2A (KAT2A) and lysine acetyltransferase 2B (KAT2B) degrader” NCT06846606 ↗ |
| Route | Oral | “AUTX-703 administered orally” NCT06846606 ↗ |
| Target | KAT2B | “lysine acetyltransferase 2B (KAT2B)” NCT06846606 ↗ |